Haleon PLC Executes Share Buyback Program in August 2025

Haleon PLC Sponsored ADR ( (HLN) ) just unveiled an update.

On August 14, 2025, Haleon PLC announced the purchase of 830,000 ordinary shares for cancellation as part of the second tranche of its share buyback program initiated on July 31, 2025. This transaction is expected to impact the company’s share capital and voting rights, with the total number of ordinary shares now at 8,972,425,583. This strategic move is likely to influence the company’s market positioning and shareholder interests.

The most recent analyst rating on (HLN) stock is a Buy with a $13.40 price target. To see the full list of analyst forecasts on Haleon PLC Sponsored ADR stock, see the HLN Stock Forecast page.

Spark’s Take on HLN Stock

According to Spark, TipRanks’ AI Analyst, HLN is a Neutral.

Haleon PLC’s overall stock score of 65 reflects a mixed outlook. Strong financial performance and strategic investments are offset by bearish technical signals and regional sales challenges, particularly in North America. The company’s valuation is moderate, aligning with its growth prospects. Continued focus on innovation and market expansion could enhance its position, but near-term challenges need to be addressed.

To see Spark’s full report on HLN stock, click here.

More about Haleon PLC Sponsored ADR

Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with humanity. The company offers products across six major categories, including Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Its well-known brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren are recognized for their trusted science and innovation.

Average Trading Volume: 14,160,841

Technical Sentiment Signal: Hold

Current Market Cap: $43.27B

Learn more about HLN stock on TipRanks’ Stock Analysis page.